
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc is positioned favorably due to its focus on developing proprietary medicines for significant unmet medical needs, particularly in oncology and COVID-19 treatment. The company's current valuation appears attractive, reflecting a positive sentiment among analysts about its potential, as indicated by an upward adjustment in the 12-month price target based on net present value (NPV) analysis. Additionally, the anticipated achievement of key clinical milestones is expected to serve as a strong catalyst for the company’s stock, suggesting a positive trajectory moving forward.
Bears say
Atossa Therapeutics reported a net loss of $8.4 million, translating to an earnings per share (EPS) of $(0.07), which fell short of both internal estimates and consensus expectations of $(0.06). The company faces significant risks, including balance sheet and liquidity issues, potential failures of its drug candidates in demonstrating safety and efficacy during clinical trials, and challenges in securing regulatory approvals. Additionally, the ability to successfully commercialize its products and ensure suitable reimbursement remains uncertain amidst heightened competition and evolving investor sentiment toward biotechnology stocks.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares